In a hypothetical example, to investigate the renoprotective effect of a novel Sodium-glucose co-transporter-2 SGLT2 inhibitor, we designed a RCT enrolling 10.000 patients with CKD stages 1–3 and randomly divided them to the active or placebo group (5000 patients in each group). Here, SLC5A2 is linked to chronic kidney disease.